|
1
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Holmes RS and Vaughan TL: Epidemiology and
pathogenesis of esophageal cancer. Semin Radiat Oncol. 17:2–9.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dawsey SM, Lewin KJ, Liu FS, Wang GQ and
Shen Q: Esophageal morphology from Linxian, China. Squamous
histologic findings in 754 patients. Cancer. 73:2027–2037. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cook MB: Non-acid reflux: The missing link
between gastric atrophy and esophageal squamous cell carcinoma? Am
J Gastroenterol. 106:1930–1932. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Y: Epidemiology of esophageal
cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Doye V, Le Gouvello S, Dobransky T,
Chneiweiss H, Beretta L and Sobel A: Expression of transfected
stathmin cDNA reveals novel phosphorylated forms associated with
developmental and functional cell regulation. Biochem J.
287:549–554. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jeon TY, Han ME, Lee YW, Lee YS, Kim GH,
Song GA, Hur GY, Kim JY, Kim HJ, Yoon S, et al: Overexpression of
stathmin1 in the diffuse type of gastric cancer and its roles in
proliferation and migration of gastric cancer cells. Br J Cancer.
102:710–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bieche I, Lachkar S, Becette V,
Cifuentes-Diaz C, Sobel A, Lidereau R and Curmi PA: Overexpression
of the stathmin gene in a subset of human breast cancer. Br J
Cancer. 78:701–709. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rana S, Maples PB, Senzer N and Nemunaitis
J: Stathmin 1: A novel therapeutic target for anticancer activity.
Expert Rev Anticancer Ther. 8:1461–1470. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akhtar J, Wang Z, Jiang WP, Bi MM and
Zhang ZP: Stathmin overexpression identifies high risk for
lymphatic metastatic recurrence in pN0 esophageal squamous cell
carcinoma patients. J Gastroenterol Hepatol. 29:944–950. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carnero A: The PKB/AKT pathway in cancer.
Curr Pharm Des. 16:34–44. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vanhaesebroeck B and Waterfield MD:
Signaling by distinct classes of phosphoinositide 3-kinases. Exp
Cell Res. 253:239–254. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi Y, Paluch BE, Wang X and Jiang X: PTEN
at a glance. J Cell Sci. 125:4687–4692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saal LH, Johansson P, Holm K,
Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA,
Malmström P, Memeo L, et al: Poor prognosis in carcinoma is
associated with a gene expression signature of aberrant PTEN tumor
suppressor pathway activity. Proc Natl Acad Sci USA. 104:pp.
7564–7569. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen J, Lan T, Zhang W, Dong L, Kang N, Fu
M, Liu B, Liu K, Zhang C, Hou J and Zhan Q: Dasatinib enhances
cisplatin sensitivity in human esophageal squamous cell carcinoma
(ESCC) cells via suppression of PI3K/AKT and Stat3 pathways. Arch
Biochem Biophys. 575:38–45. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu J and Hu Z: Y-box-binding protein 1
promotes tumor progression and inhibits cisplatin chemosensitivity
in esophageal squamous cell carcinoma. Biomed Pharmacother.
79:17–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang W, Wang Z and Jia Y: CEP55
overexpression predicts poor prognosis in patients with locally
advanced esophageal squamous cell carcinoma. Oncol Lett.
13:236–242. 2017.PubMed/NCBI
|
|
21
|
Sun Z, Ji N, Bi M, Zhang Z, Liu X and Wang
Z: Negative expression of PTEN identifies high risk for
lymphatic-related metastasis in human esophageal squamous cell
carcinoma. Oncol Rep. 33:3024–3032. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Akhtar J, Wang Z, Zhang ZP and Bi MM:
Lentiviral-mediated RNA interference targeting stathmin1 gene in
human gastric cancer cells inhibits proliferation in vitro and
tumor growth in vivo. J Transl Med. 11:2122013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rice TW, Rusch VW, Ishwaran H and
Blackstone EH; Worldwide Esophageal Cancer Collaboration, : Cancer
of the esophagus and esophagogastric junction: Data-driven staging
for the seventh edition of the American Joint Committee on
Cancer/International Union against cancer cancer staging manuals.
Cancer. 116:3763–3773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nieman DR and Peters JH: Treatment
strategies for esophageal cancer. Gastroenterol Clin North Am.
42:187–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fesik SW: Promoting apoptosis as a
strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cajone F and Sherbet GV: Stathmin is
involved in S100A4-mediated regulation of cell cycle progression.
Clin Exp Metastasis. 17:865–871. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Belletti B and Baldassarre G: Stathmin: A
protein with many tasks. New biomarker and potential target in
cancer. Expert Opin Ther Targets. 15:1249–1266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang C, Chakravarty D, Sakabe I, Mewani
RR, Boudreau HE, Kumar D, Ahmad I and Kasid UN: Role of SCC-S2 in
experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9
expression. Mol Ther. 13:947–955. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Janzen V and Scadden DT: Stem cells: Good,
bad and reformable. Nature. 441:418–419. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Di Cristofano A and Pandolfi PP: The
multiple roles of PTEN in tumor suppression. Cell. 100:387–390.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shah A, Swain WA, Richardson D, Edwards J,
Stewart DJ, Richardson CM, Swinson DE, Patel D, Jones JL and
O'Byrne KJ: Phospho-akt expression is associated with a favorable
outcome in non-small cell lung cancer. Clin Cancer Res.
11:2930–2936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tang JM, He QY, Guo RX and Chang XJ:
Phosphorylated Akt overexpression and loss of PTEN expression in
non-small cell lung cancer confers poor prognosis. Lung Cancer.
51:181–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Panigrahi AR, Pinder SE, Chan SY, Paish
EC, Robertson JF and Ellis IO: The role of PTEN and its signalling
pathways, including AKT, in breast cancer; an assessment of
relationships with other prognostic factors and with outcome. J
Pathol. 204:93–100. 2004. View Article : Google Scholar : PubMed/NCBI
|
